Demographic characteristics of study participants. حسب Lijuan Liu (136685)

الموضوعات:

Results of Analysis of Co-variance (ANCOVA) for change in parameter predicted by treatment group with pre-treatment value as a covariate. * p < 0.05; ** p < 0.01. حسب Lijuan Liu (136685)

الموضوعات:

Comparison of treatment effects between premolar extraction and mandibular third molar extraction groups. * p < 0.05; ** p < 0.01. حسب Lijuan Liu (136685)

الموضوعات:

Intraoperative facial and intraoral photographs of the case with mandibular third molar extraction. حسب Lijuan Liu (136685)

الموضوعات:

Pretreatment facial, intraoral photographs, and radiographs of the case with premolar tooth extraction. حسب Lijuan Liu (136685)

الموضوعات:

Pretreatment facial, intraoral photographs, and radiographs of the case with mandibular third molar extraction. حسب Lijuan Liu (136685)

الموضوعات:

The results of KEGG enrichment analysis (Annotation: Circles represent each pathway, and the redder the color, the larger the circle, and the more important it is). حسب Lin Zhou (141050)

Traits at cellular, leaf, and whole-plant scales which were significantly different [increased (↑) or decreased (↓)] or non-significant between tolerant and sensitive cultivars in... حسب Ranjeeta Adhikari (9905958)

CBP per cumulative year for daratumumab and pembrolizumab per vial. حسب R. J. S. D. Heine (17889199)

الموضوعات:

S4 Fig - حسب R. J. S. D. Heine (17889199)

الموضوعات:

S1 Fig - حسب R. J. S. D. Heine (17889199)

الموضوعات:

S5 Fig - حسب R. J. S. D. Heine (17889199)

الموضوعات:

Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial. حسب R. J. S. D. Heine (17889199)

الموضوعات:

S3 Fig - حسب R. J. S. D. Heine (17889199)

الموضوعات:

S6 Fig - حسب R. J. S. D. Heine (17889199)

الموضوعات:

CBP per cumulative indication for daratumumab and pembrolizumab per vial. حسب R. J. S. D. Heine (17889199)

الموضوعات:

Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation. حسب R. J. S. D. Heine (17889199)

الموضوعات:

Implementation of indication-based pricing (10^th scenario) for daratumumab and pembrolizumab. حسب R. J. S. D. Heine (17889199)

الموضوعات:

Scenario analysis for daratumumab using a cumulative cost-based price per year per vial. حسب R. J. S. D. Heine (17889199)

الموضوعات:

Input parameters for the base-case analysis. حسب R. J. S. D. Heine (17889199)

الموضوعات: